Terminology Service < Semantic Lookup Platform

All terms in CHEBI

Label	Id	Description
N-acetyl-9-O-acetyl-alpha-neuraminic acid	CHEBI_84941	[A member of the class of N-acetylneuraminic acids that is alpha-neuraminic acid which has acetylated on N-5 and O-9.]
EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor	CHEBI_145410	[An EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor) inhibitor that interferes with the action of any isocitrate dehydrogenase (EC 1.1.1.42).]
4-{[(4-aminophenyl)sulfonyl]amino}hexanoic acid	CHEBI_145411	[A sulfonamide consisting of hexanoic acid with a 4-aminobenzenesulfonamido group at its 6-position.]
glasdegib	CHEBI_145428	[A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a (2R,4S)-4-{[(4-cyanophenyl)carbamoyl]amino}-1-methylpiperidin-2-yl group at position 2. It is a hedgehog signalling pathway inhibitor that acts by binding to Smoothened (SMO) receptors and blocking signal transduction (IC50 = 5 nM). It is used in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients (aged >= 75 years), or who have medical conditions that prevent the use of standard chemotherapy.]
SMO receptor antagonist	CHEBI_66908	[An antagonist that interferes with the action of smoothened (SMO) receptor.]
Hedgehog signaling pathway inhibitor	CHEBI_140921	[Any pathway inhibitor that inhibits the Hedgehog signalling pathway.]
sapacitabine	CHEBI_145429	[A nucleoside analogue resulting from the formal condensation of the carboxy group of hexadecanoic acid with the amino group of CNDAC. It is the prodrug of CNDAC and is currently in clinical development for the treatment of acute myeloid leukemia (AML).]
CNDAC	CHEBI_145435	[A pyrimidine 2'-deoxyribonucleoside that is 2'-deoxycytidine having a cyano group in the 2'-position. It is the active metabolite of the anti-cancer drug, sapacitabine which is currently in clinical development for the treatment of hematologic malignancies and solid tumors.]
6-O-sulfonato-D-glucono-1,5-lactone(1-)	CHEBI_145424	[Anion of 6-O-sulfono-D-glucono-1,5-lactone arising from deprotonation of the sulfate OH group; major species at pH 7.3.]
1-O-(4-O-benzyl-alpha-D-galactosyl)-N-hexacosanoylphytosphingosine	CHEBI_145426	[A glycophytoceramide having a 4-O-benzyl-alpha-D-galactosyl residue at the O-1 position and a hexacosanoyl group attached to the nitrogen. One of a series of an extensive set of 4"-O-alkylated alpha-GalCer analogues evaluated (PMID:30556652) as invariant natural killer T-cell (iNKT) antigens.]
D-glucopyranose 6-sulfate(1-)	CHEBI_145427	[An organosulfate oxoanion resulting from deprotonation of the sulfate OH group of D-glucopyranose 6-sulfate; major species at pH 7.3.]
D-glucopyranose 6-sulfate	CHEBI_145436	[A monosaccharide sulfate that is D-glucopyranose carrying a single sulfo substituent at position 6.]
2-deoxy-6-O-phosphonato-D-glucono-1,5-lactone(2-)	CHEBI_145420	[Dianion of 2-deoxy-6-O-phosphono-D-glucono-1,5-lactone arising from deprotonation of the phosphate OH groups; major species at pH 7.3.]
rigosertib sodium	CHEBI_145421	[The sodium salt of rigosertib. It is an anti-cancer agent which has been granted Orphan Drug Designation by the FDA for use in patients with myelodysplastic syndromes (MDS).]
2-amino-2-deoxy-6-O-phosphonato-D-glucono-1,5-lactone(2-)	CHEBI_145423	[Dianion of 2-amino-2-deoxy-6-O-phosphono-D-glucono-1,5-lactone arising from deprotonation of the phosphate OH groups; major species at pH 7.3.]
1,2-dioleoyl-sn-glycero-3-diphosphate(3-)	CHEBI_145439
1,2-diacyl-sn-glycerol 3-diphosphate(3-)	CHEBI_59996	[Trianion of 1,2-diacyl-sn-glycerol 3-diphosphate arising from deprotonation of the diphosphate OH groups.]
CHEBI_336019	CHEBI_336019
indisulam	CHEBI_145431	[A chloroindole that is 3-chloro-1H-indole substituted by a [(4-sulfamoylphenyl)sulfonyl]nitrilo group at position 7. It is a carbonic anhydrase inhbitor and a potential anti-cancer agent currently in clinical development.]
EC 4.2.1.1 (carbonic anhydrase) inhibitor	CHEBI_23018	[An EC 4.2.1.* (hydro-lyases) inhibitor that interferes with the action of carbonic anhydrase (EC 4.2.1.1). Such compounds reduce the secretion of H(+) ions by the proximal kidney tubule.]